ObjectiveTo evaluate the clinical efficacy of a combination therapy with capreomycin, levofloxacin and sodium aminosalicylate in the treatment of multidrug resistant pulmonary tuberculosis ( MDRPTB). MethodsOne hundred and twenty patients with MDRPTB were divided  into treatment group（60 cases） and control group（60 cases）. In the treatment group, patients mainly received treatment of capreomycin, levofloxacin and sodium aminosalicylate, and combined with rifapentine, isoniazid  and  pyrazinamide; in control group, patients mainly received treatment of amikacin, ethambutol, combined treatment was the same with that of treatment group, the course of treatment were both 16 months. ResultsAll patients received 16 months treatment, the sputum negative conversion rate of the treatment group was 83.33%, which was significantly higher than 65.00% of control group (χ2=5.26, P=0.02); The focal absorption rate and cavity closure rate in treatment group was 90.00% and 71.43% respectively, which was obviously higher than 66.67% and 31.25% of control group respectively (χ2=9.62, P=0.00; χ2=10.82, P=0.00); Adverse effects  in treatment group and control group was 35.00% and 33.33% respectively, there was no significant difference between two groups  (χ2=0.04, P=0.85). ConclusionThe combination treatment  of  capreomycin, levofloxacin  and sodium aminosalicylate is effective and safe for patients with MDRPTB.